Quantinno Capital Management LP Boosts Stake in Natera, Inc. $NTRA

Quantinno Capital Management LP grew its position in Natera, Inc. (NASDAQ:NTRA) by 8.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 61,550 shares of the medical research company’s stock after acquiring an additional 5,007 shares during the period. Quantinno Capital Management LP’s holdings in Natera were worth $12,310,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Horizon Investments LLC grew its stake in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its position in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the period. Savvy Advisors Inc. boosted its holdings in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares during the period. Parallel Advisors LLC grew its position in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares during the last quarter. Finally, First Horizon Corp grew its holdings in shares of Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after buying an additional 51 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on NTRA. Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price objective for the company. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Natera in a research report on Monday, July 6th. Wells Fargo & Company increased their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. The Goldman Sachs Group started coverage on Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective for the company. Finally, Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Trading Up 1.0%

NASDAQ:NTRA opened at $270.36 on Tuesday. The firm’s fifty day simple moving average is $248.11 and its 200 day simple moving average is $222.36. The firm has a market capitalization of $38.72 billion, a price-to-earnings ratio of -165.87 and a beta of 1.51. Natera, Inc. has a twelve month low of $133.01 and a twelve month high of $288.04.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total value of $818,700.00. Following the completion of the transaction, the insider owned 134,643 shares of the company’s stock, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 173,469 shares of company stock valued at $39,310,838 in the last three months. 5.05% of the stock is currently owned by company insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.